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Abstract
Purpose: The hypoxic microenvironment of glioblastoma multiforme (GBM) is thought to increase resistance to cancer
therapies. Recent evidence suggests that hypoxia induces protein phosphatase 2A (PP2A), a regulator of cell cycle and cell
death. The effects of PP2A on GBM tumor cell proliferation and survival during hypoxic conditions have not been studied.
Experimental Design: Expression of PP2A subunits and HIF-a proteins was measured in 65 high-grade astrocytoma and 18
non-neoplastic surgical brain specimens by western blotting. PP2A activity was measured by an immunoprecipitation assay.
For in vitro experiments, GBM-derived tumor stem cell-like cells (TSCs) were exposed to severe hypoxia produced by either
CoCl2 or 1% O2. PP2A activity was inhibited either by okadaic acid or by shRNA depletion of the PP2A C subunit. Effects of
PP2A activity on cell cycle progression and cell survival during hypoxic conditions were assessed using flow cytometry.
Results: In our patient cohort, PP2A activity was positively correlated with HIF-1/ protein expression (P=0.002). Patients
with PP2A activity levels above 160 pMP had significantly worse survival compared to patients with levels below this
threshold (P=0.002). PP2A activity was an independent predictor of survival on multivariable analysis (P=0.009). In our in
vitro experiments, we confirmed that severe hypoxia induces PP2A activity in TSCs 6 hours after onset of exposure. PP2A
activity mediated G1/S phase growth inhibition and reduced cellular ATP consumption in hypoxic TSCs. Conversely,
inhibition of PP2A activity led to increased cell proliferation, exhaustion of intracellular ATP, and accelerated P53-
independent cell death of hypoxic TSCs.
Conclusions: Our results suggest that PP2A activity predicts poor survival in GBM. PP2A appears to reduce the metabolic
demand of hypoxic TSCs and enhances tumor cell survival. Modulation of PP2A may be a potential target for cancer
therapy.
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Introduction
Glioblastoma multiforme (GBM) account for approximately
70% of all malignant astrocytomas and leave patients with a
median survival of 15 months despite aggressive therapies
including surgical resection, radiation, and chemotherapy [1].
Pathological characteristics of GBM include hypercellularity,
vascular endothelial proliferation, and foci of necrosis surrounded
by pseudopalisades [2]. The imbalance between rapidly prolifer-
ating cells, which are driven by RTK/RAS/PI3K signaling
[3,4,5], and a poorly organized vasculature gives rise to a severely
hypoxic microenvironment in GBM [6]. Severe cellular hypoxia in
GBM is further aggravated by intravascular thrombosis due to up-
regulation of tissue factor [7]. Ultimately, this leads to areas of
necrosis surrounded by densely packed hypoxic astrocytoma cells,
which are less proliferative and show a higher level of apoptosis
compared to adjacent cells [8]. Pseudopalisades with severely
hypoxic conditions have been proposed to select for more
malignant and invasive neoplastic cells. Moreover, the slowly
cycling nature of hypoxic tumor cells makes them more resistant to
chemotherapy and irradiation [9]. Understanding the mechanisms
that mediate tumor cell dormancy in response to oxygen
deprivation could provide potential targets for therapeutic
intervention.
Recent studies have shown that hypoxia induces enzymatic
activity of protein phosphatase 2A (PP2A) in both in vivo [10] and
in vitro [11,12] models. PP2A is a heterotrimer consisting of an
active core dimer, composed of the catalytic subunit (C subunit)
and a scaffold protein (A subunit), which is joined by a regulatory
subunit (B subunit) that dictates substrate specificity and enzyme
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30059activity [13]. A multitude of families, isoforms, and splice variants
of the B subunit allow for the generation of more than 60 different
heterotrimeric PP2A holoenzymes [14]. The complexity of the
PP2A composition provides the molecular basis necessary for
regulation of many cellular processes including proliferation,
malignant transformation, differentiation, and apoptosis. The
involvement of PP2A in regulation of cell proliferation was initially
discovered when okadaic acid (OA), a PP2A inhibitor [15], was
found to promote tumor growth in skin [16], stomach, and liver
cancer models [17]. Inhibition of PP2A by various agents such as
OA, SV 40, small tumor antigen, or PME has been shown to
augment cellular proliferation in part by activation of RTK/RAS/
PI3K signaling [18,19]. PP2A also regulates cell proliferation by
controlling cell cycle progression. Induction of PP2A activity by
ceramide inhibits cell growth and leads to G1/S cell cycle arrest
[20]. A previous study proposed that PP2A may mediate its effects
on cell cycle progression as a physical complex with cyclin G2
[21]. Cyclin G2 is an unconventional cyclin that, independent of
P53, causes cell cycle arrest or apoptosis [22]. Glioma and other
cell lines up-regulate cyclin G2 in response to hypoxic conditions
[23,24,25]. However, the role of PP2A signaling and cell cycle
arrest in hypoxic tumor stem cells remains unclear.
In the current study, we aimed to investigate PP2A protein
expression and activity in GBM. Moreover, we attempted to study
whether hypoxia induces PP2A activity in GBM and whether
PP2A activity is involved in regulation of cell cycle progression and
survival of severely hypoxic tumor cells.
Methods
Patient cohort and surgical tissue samples
A total of 65 tumor samples were analyzed for this study.
According to World Heath Organization (WHO) criteria, 62
samples were histologically characterized as grade IV glioblastoma
multiforme (GBM) and three samples as grade III astrocytoma [2].
In five patients, tumor samples were collected from the initial tumor
resection and again during resection of recurrent tumor. Minimum
one-year clinical follow-up data was available on 54 GBM patients.
Non-neoplastic brain tissue samples were collected from 18 patients
who underwent temporal lobectomy for medically intractable
seizures. All surgical tissue specimens were reviewed by our
attending neuropathologist to ensure that each specimen was
histologically consistent with either high grade astrocytoma or
controltissue withoutevidenceofneoplasia.Controltissue,however
was not entirely normal neocortex. Pathological review detected
neuronal dysplasia and gliosis in 6 specimens and focal neuronal
damage in 4 of our 18 control specimens. Tumor volume was
estimated by an ellipsoid model using the product of the maximal
anteroposterior, lateral, and rostrocaudal radius measured on
preoperative contrast-enhanced MR studies [26]. This study was
approved bytheWeillCornellMedicalCollege InstitutionalReview
Board. Written informed consent was obtained from all patients
prior to inclusion in the current study.
Genomic data from the Cancer Genome Atlas
PP2A-C gene expression data of the Cancer Genome Atlas [3]
was analyzed using the cBIO Cancer Genomics Portal (http://
www.cbioportal.org). Analysis was carried out in 197 primary GBM
following exclusion of secondary GBMs harboring IDH mutations
[27,28]. Z-scores were used to assess expression of mRNA.
Generation of tumor stem-like cells
Operative tissue specimens were placed on ice immediately
following harvest, mechanically dissected, and enzymatically
dissociated at 37 Cu for 30 minutes in PIPES/EDTA buffer
containing papain (543 mgP/ml) and DNAse (8 U/ml). The
resultant suspension was triturated using Pasteur pipettes to single
cell suspension from cellular aggregates and filtered through a
70 mm nylon mesh. Enzymatic activity was quenched by adding
1 ml of fetal bovine serum followed by centrifugation for
5 minutes at 600 rpm. Supernatant was removed, and the pellet
was resuspended and incubated in 10 ml of RBC lysis buffer
(Invitrogen) for 10 minutes. After a second spin, cells were re-
suspended in stem cell medium consisting of DMEM/F12
containing B27 (Gibco), N2 (Gibco), 20 ng/ml EGF, basic-FGF
(Invitrogen), L-glutamine (2 mM, Gibco), pyruvate (1 mM,
Gibco), bovine serum albumin fraction V (0.06%, Gibco), and
antibiotic/anti-mycotic (Gibco). They were then seeded at a
density of 1610
6 cells per 10 cm cell culture dish (Nunc). Tumor
stem-like cells (TSCs) were propagated as adherent cells in culture
dishes coated with laminin (Sigma) at 10 mg/ml for 2 hrs prior to
use [29]. The medium was refreshed every 48–72 hours. Prior to
use in experiments, the tree TSCs used in the current study (334,
974 and 980) underwent a series routine tests confirming
expression of stem cell markers, self-renewal, differentiation and
tumorigenicity [30,31] (Figure S1). TSCs were used for experi-
ments between passage 5 and passage 20.
Western blots
Tumor and non-neoplastic tissue samples were immediately
placed on ice, dissected, and suspended in lysis buffer containing
2 mM EDTA, 0.15 M NaCl, and 10% glycerol. Following
dissociation of the tissue using a glass grinder, extracts were
collected by centrifugation at 14,0006 g in a centrifuge at 4uC.
Protein concentration was determined using a BCA protein assay
kit (Thermo Scientific, IL, USA), and each lane was loaded with
35 mg of extract. Protein samples were separated by 4–12% SDS-
PAGE and electrophoretically transferred to PVDF membranes.
Membranes were subsequently blocked in 16TBS-Tween20 with
5% BSA for 1 hr followed by incubation in primary antibody
overnight at 4 Cu under gentle agitation. Primary antibodies raised
in rabbits against PP2A-B (PR 55, Cell signaling), P53 (Cell
signaling), Phospho-P53 (S15, Cell signaling), b-actin (Cell
signaling), HIF-2a (Abcam), and HIF-1a (Novus Biologicals),
raised in mice against PP2A-C (BD Transduction Laboratories),
HIF-1a (BD Transduction Laboratories), cyclin G2 (Abcam), and
PME-1 (Santa Cruz Biotechnology), and raised in rat against
PP2A-A (6F9, Covance) were used. Following three washes in
TBS-Tween20, membranes were incubated in appropriate HRP-
conjugated secondary antibody (Jackson ImmunoResearch) for
1 hr at room temperature. Immunoblotting was visualized by ECL
detection solution (Thermo Scientific) for 5 minutes at room
temperature.
Immunoprecipitation
A total of 500 mg of protein extract was incubated with
antibodies directed against PP2A-C (clone 1D6, Millipore) and
Protein A agarose (30 ml) in 450 ml of RIPA buffer under constant
agitation at 4u overnight. Following 3 washes with RIPA buffer,
the sample was resuspended in electrophoresis sample buffer and
processed as described above. The membrane was probed with
antibodies directed against PP2A-C (6F9, Covance) and cyclin G2
(ProSci).
PP2A activity assay
TSCs were plated at a density of approximately 20,000 cells per
cm
2 and cultured overnight. The next day, medium was replaced
with fresh cell culture medium and cells were exposed to hypoxia
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supplementing media with cobalt chloride (CoCl2) at a concen-
tration of 200 mM. Cells were lysed at indicated time points using
cell lysis buffer (Cell Signaling Technology) supplemented with
protease inhibitor (Sigma-Aldrich). Lysates from each treatment
group containing 100 mg protein were tested using a Malachite
Green Phosphatase assay specific for serine/threonine phospha-
tase activity (Millipore). Measurements of PP2A activity in tumor
samples and normal brain tissue samples were performed in the
same conditions.
Viral infections
TSCs were plated in 6-well plates at 50% confluency. The next
day medium was changed to medium containing 5 mg/ml of
polybrene and 20 ml of lentiviral particles encoding shRNA
directed against random RNA (Control) PP2A-C/, PME-1 or
P53 (Santa Cruz Biotechnology). After 12 hours, the supernatant
was removed and replaced with stem cell medium. One day later,
cells were split 1:3, grown for additional 2 days, and then selected
with 2 mg/ml of puromycin. After 1 week in culture, puromycin
dose was decreased to a maintenance concentration of 0.5 mg/ml.
MTT and ATP assay
TSCs were plated in 96-well plates at a density of 20,000 cells
per cm
2. The following day media was replaced with fresh media.
Hypoxia was induced by supplementing media with 200 mMo f
CoCl2 or by incubation in 1% hypoxia. At the same time OA was
added for inhibition of PP2A as indicated. Viability and metabolic
activity was assessed using an MTT kit according to the
manufacturers instructions (Roche). ATP intracellular concentra-
tion was measured using the ViaLightH assay according to
manufacturers instructions (Lonza). For measurement of the
ATP decay following substrate deprivation, TSCs were incubated
in D5030 media (Sigma) supplemented with 25 mmol/L HEPES
without glucose.
Flow cytometry
Cells were plated in 6-well plates at a density of 20,000 cells per
cm
2. After 24 hours, media was replaced with either normal
growth media or media supplemented with 200 mM of CoCl2
and/or okadaic acid Following a 24-hour period, cells were
exposed to a 1-hour pulse of 10 mM of BrdU, fixated, labeled with
anti-BrdU antibody and total DNA was stained with 7-AAD
(BrdU Flow Kit, BD Pharmingen). Following 1 week of hypoxia
induced by either CoCl2 or 1% of hypoxia, apoptosis and cell
death were assessed using Annexin V-FITC and Propidium Iodine
(Trevigen). Fluorescence-activated cell sorting (FACS) analysis was
carried out on 10,000 cells using a Becton-Dickinson FACScan
(Becton Dickinson).
Statistics
Continuous variables are presented as means 6 standard error
of mean. Categorical values are given as percentages. Correlations
between continuous variables were calculated using Pearson’s
correlation analysis. Differences in continuous variables between
two groups were assessed by a Mann-Whitney U-test and between
three or more groups by ANOVA followed by Tukey post-hoc
analysis. Kaplan-Meier survival analysis was performed for
patients with high and low PP2A activity levels dichotomized at
160 pMP. Significant differences in survival were calculated using
the log-rank test. Variables with significant prediction of survival
in univariate analysis were entered into a multivariable analysis
using the Cox’s regression model. The model was built in a
conditional forward stepwise fashion [32]. A P-value of less than
0.05 was considered significant. Statistical analyses were per-
formed using SPSS (Version 19.0 for Macintosh).
Results
PP2A subunits exhibit a heterogenous expression
pattern in surgical GBM specimen
A total of 65 high-grade astrocytoma specimens from 60
patients were examined (Table 1). Patients were predominantly
male (61.7%) and on average 56.7 years old. Altered mental status,
seizures and/or headaches were the most common presenting
symptoms. At the time of initial presentation, the mean Karnofsky
score was 79.5. The average tumor volume was 43.9 cm
3. Protein
expression levels of all three PP2A subunits were analyzed in non-
neoplastic brain tissue compared to GBM samples. Homogeneous
expression levels of the A, B, and C subunits were detected in the
18 normal brain specimens. Consistent with a previous report
[33], expression levels of the three subunits were decreased to
variable degrees in the GBM specimens (Figure 1A and B). On
average, PP2A expression was reduced by approximately one third
in GBM compared to normal tissue samples (Figure 1A and B).
There was a significant positive correlation between expression
levels of the A and C subunits (Pearson Correlation Coefficient
0.76, P,0.001, Figure 1A).
High PP2A activity is associated with poor prognosis in
GBM patients
PP2A activity was measured in non-neoplastic brain specimens
and in GBM samples. There was a tendency towards lower PP2A
activity level in GBM specimens (344.1676.6 pMP) compared to
control brain tissue (448.76166.7 pMP). However, this difference
did not reach statistical significance due to great variability in both
groups. PP2A activity followed a significant correlation with the
protein expression of the C subunit (Pearson Correlation
Coefficient 0.334, P=0.003, Figure 1C). Patients with tumors
exhibiting PP2A activity above 160 pMP had a significantly worse
prognosis compare to patients with low PP2A activity (P=0.002).
Thus, patients with high PP2A activity had a median survival of
8.1 months (confidence interval 6.6–9.6 months) compared to
patients with low PP2A activity who lived 21.0 months (confidence
interval 10.4–31.5 months, Figure 1E). The impact of PP2A
Table 1. GBM Patient Characteristics (n=60).
Age 56.7612.5 yrs
Gender Male 37 (61.7%)
Female 23 (38.3%)
Karnofsky score 79.5614.9
Main presenting symptom Altered mental status 20 (33.3%)
Seizure 15 (25.0%)
Headache 11 (18.3%)
Visual Impairment 7 (11.7%)
Aphasia 5 (8.3%)
Tumor volume at presentation 43.9634.9 cm
3
Recurrent tumor Yes 19 (31.7%)
No 38 (63.3%)
N/A 3 (5.0%)
doi:10.1371/journal.pone.0030059.t001
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patients who underwent their initial surgical resection (Figure 1F).
In this subgroup, median survival of individuals with high PP2A
activity was 7.7 months (confidence interval 5.9–9.6 months)
compared to 31.0 months of patients with low PP2A activity
(confidence interval 16.4–45.6 months, P,0.001). In the same
subset of patients, PP2A-C protein expression levels were
associated with a tendency towards worse survival (Figure 1G).
In order to account for known predictors of survival such as age
and Karnofsky score [34] a multivariable analysis was performed.
PP2A activity remained an independent predictor on survival
(P=0.009, Table 2). Importantly, independent validation of our
results was obtained by analyzing mRNA expression data from the
Cancer Genome Atlas (TCGA) [3]. Patients with elevated PP2A-C
mRNA expression (one standard deviation above the mean
expression) had a significantly worse prognosis (P=0.0014)
compared to patients with lower expression levels (Figure 1E). In
patients with high PP2A-C mRNA expression, the median survival
was 7.7 months (confidence interval 4.7–13.0 months) compared
to 13.6 months (confidence interval 11.9–15.4 months) in patients
with low PP2A mRNA expression.
PP2A mediates G1/S phase growth inhibtion during
severe hypoxia
In order to estimate the degree of hypoxia in our high-grade
glioma specimens, we measured HIF-a protein expression. In the
presence of oxygen, members of the alpha family of hypoxia-
responsive proteins are continuously degraded and levels are low.
During hypoxic conditions degradation is inhibited and the
protein accumulates [35,36]. Heterogeneous HIF-1a expression
was detected in both control and GBM samples (Figure 1A). In
non-neoplastic tissue higher HIF-1a expression was detected in
specimens with neuronal dysplasia (n=6) or focal neurological
damage (n=4) compared to control tissue with entirely normal
histopathological appearance (n=8, 1.6 relative intensity com-
pared to 0.6 relative intensity, P=0.002). In our cohort, HIF-1a
expression was correlated with PP2A activity (Figure 1D, Pearson
Correlation Coefficient 0.36, P=0.002), while no correlation was
detected between HIF-2a protein expression and PP2A-activity
(Pearson correlation coefficient 0.027, P=0.897).
We then studied the response of GBM-derived TSCs to hypoxia
in vitro. Hypoxia led to increased HIF-a protein expression in
TSCs (Figure 2A and Figure S2). Increased HIF-1a protein levels
were consistently detected 2 hours following exposure to hypoxia
while elevated HIF-2a protein levels were first noted at 72 hours.
We then examined whether hypoxic conditions would induce
PP2A activity of TSCs in vitro. First, we measured PP2A activity of
TSCs grown in standard culturing conditions and found some
baseline variation. For example, high PP2A activity was routinely
detected in cultures that were highly confluent or had been
propagated for several days without replating. Conversely, low
PP2A activity was consistently observed in cell cultures that were
plated at a density of 20,000 cells per cm
2 within the previous
24 hours. Next, in order to test whether hypoxic conditions lead to
increased PP2A activity in vitro, we exposed GBM-derived TSCs to
hypoxia. While PP2A activity of TSCs grown at 80% confluency
was low one day after plating, activity increased markedly from
6 hours onwards following exposure to CoCl2 (Figure 2A) or 1%
hypoxia (Figure S2A). Given that cyclin G2, a binding partner of
PP2A [22], has been shown to be upregulated in cancer cells in
response to hypoxic conditions [23,24,25], we studied its temporal
expression pattern in relation to PP2A activity following exposure
to hypoxia. Six hours following supplementation of culture
medium with CoCl2 and 12 hours following exposure to 1%
hypoxia increased cyclin G2 expression levels were observed
(Figure 2A, Figure S2). Elevated cyclin G2 expression levels
mirrored the rise of PP2A activity. An immunoprecipitation assay
confirmed that cyclin G2 formed a complex with PP2A-C in TSCs
during both normoxic and hypoxic conditions (Figure 2B).
In order to explore the role of PP2A activity in hypoxic TSCs,
we studied the effects of PP2A inhibition. During normoxic
culturing conditions, inhibition of PP2A did not significantly alter
ATP consumption rate of TSCs (Figure 3A). Conversely, during
hypoxic conditions PP2A inhibition significantly increased ATP
consumption of TSCs (Figure 3A). To further investigate the role
of PP2A on the energy status of hypoxic TSCs we analyzed
Table 2. Cox multivariate analysis for survival prediction.
Hazard
ratio SE P-value
95% Confidence
interval
Age 1.046 0.015 0.002 1.016–1.076
Karnofsky score 0.957 0.014 0.002 0.931–0.984
PP2A activity 1.001 0.000 0.009 1.000–1.001
doi:10.1371/journal.pone.0030059.t002
Figure 1. PP2A activity in GBM samples predicts poor survival. (A) Western blots of non-neoplastic brain tissue and GBM probed with
antibodies directed against HIF-1a as well as against A, B and C PP2A subunits. The first control brain tissue sample exhibits neuronal dysplasia and
gliosis on pathological review and expresses higher HIF-1a levels compared to the second control specimen with entirely normal histology. GBM
specimens express variable levels of HIF-1a and PP2A subunits. Bar diagram represents PP2A activity of each sample analyzed in the western blot
above. (B) Protein expression of all three PP2A subunits is significantly lower in GBM specimens (n=65) compared to normal brain tissue (n=18). (C)
Protein expression levels of the PP2A C subunit are significantly correlated with PP2A activity (Pearson Correlation Coefficient 0.334, P=0.003, Trend
line R
2=0.093). (D) HIF-1a protein expression levels correlate significantly with PP2A activity (Pearson Correlation Coefficient 0.36, P=0.002, Trend
line R
2=0.184). (E) In our patient cohort, high PP2A activity is associated with poor prognosis. Kaplan Meyer analysis reveals significantly worse overall
survival of patients with PP2A activity above 160 pMP (dotted line, n=24) compared to patients with levels below 160 pMP (solid line, n=36,
P=0.002). Thus median survival of patients with high PP2A activity is 8.1 months (confidence interval 6.6–9.6 months) compared to 21.0 months of
patients with low PP2A activity (confidence interval 10.4–31.5 months). (F) The impact of PP2A activity on prognosis is more pronounced in patients
at time of initial surgery. In this subgroup, median survival of patients with high PP2A activity is 7.7 months (n=16, confidence interval 5.9–9.6
months) compared to 31.0 months of patients with low PP2A activity (n=22, confidence interval 16.4–45.6 months, P,0.001). (G) At the time of initial
surgery, patients with high PP2A-C protein expression (PP2A-C.1 relative intensity [RI]) exhibit a tendency towards worse overall survival (median
survival 8.2 months, confidence interval 5.1–11.3 months) compared to patients with low expression (PP2A-C#1 RI, median survival 28.1 months,
confidence interval 11.1–43.8 months, P=0.07). (H) High PP2A mRNA expression predicts poor survival in an independent dataset derived from the
cancer genome atlas [3]. Patients with elevated PP2A-C mRNA expression (One standard deviation above the mean expression, dotted line, n=17)
had a significantly worse prognosis (P=0.0014) compared to patients with lower expression levels (solid line, n=179). In patients with high PP2A-C
mRNA expression, the median survival was 7.7 months (confidence interval 4.7–13.0 months) compared to 13.6 months (confidence interval 11.9–
15.4 months) in patients with low PP2A mRNA expression.
doi:10.1371/journal.pone.0030059.g001
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hypoxia. PP2A inhibition significantly delayed adaptive reduction of
metabolicactivityaswellasATPproductioninhypoxicTSCsduring
the first 24 hours(Figure S3D).Later,increased metabolic rate/ATP
demand by PP2A inhibition exhausted intracellular ATP levels. At 1
week following exposure, PP2A inhibition caused significant
depletion of intracellular ATP in hypoxia TSCs. Similarly, PP2A
inhibition led to decreased cell proliferation and viability of TSCs at
1 week following exposure to hypoxia (Figure S3B and C). To test
whether exhaustion of intracellular ATP during PP2A-inhibtion of
TSCs was caused by substrate deprivation, we repeated experiments
in high glucose containing media. Supplementation of culture media
with high concentration of glucose partially prevented exhaustion of
ATP in TSCs grown for one week in in hypoxic conditions with
concomitant PP2A inhibition (Figure S3E).
Cell cycle analysis revealed that TSCs exposed to hypoxic
conditions for 24 hours exhibited G1/S phase growth inhibition
(Figure 3B and C). While low doses of OA had only minimal effect
on cell cycle progression of TSCs grown in standard culturing
conditions, OA reversed the G1/S phase growth inhibition in a
dose-dependent fashion in TSCs exposed to CoCl2 for 24 hours.
In addition, a concomitant significant increase of TSCs progress-
ing into S phase was observed. The role of PP2A on G1/S phase
progression was further investigated in TSCs transduced with
shRNA directed against random RNA (control), PP2A-C, or
PME-1, which is an intrinsic antagonist of PP2A-C [19]. Depletion
of PP2A-C promoted G1/S transition. Thus, three times fewer
TSCs were found in the G1 phase following depletion of PP2A-C.
By contrast, PME-1 depletion doubled the number of TSCs
observed in the G1 phase (Figure 3D).
PP2A activity increases cell survival during severe
hypoxia
While PP2A inhibition partially sustained cell proliferation
during the first 24 hours of hypoxia, long-term PP2A inhibition
eventually lead to decreased cell viability at one to two weeks
(Figure S3B and C). In order to explore the mechanism underlying
decreased viability caused by OA, TSCs grown in either normoxia
or hypoxia for 1 week were stained with annexin/PI and subjected
to flow cytometry. As expected, few dead TSCs were detected
during normal culturing conditions (Figure 4A–C). Also, in line
with our MTT results, exposure of TSCs to low doses of OA
during normoxia had minimal effect on cell death. We then
inhibited PP2A in TSCs propagated in hypoxic conditions for
seven days. At that time, only a small amount of acute apoptosis
was detected (1.960.3%, Annexin V +/PI 2, Figure 4A). PP2A
inhibition by 1 nM of OA led to a small increase of acute
apoptosis during hypoxic conditions (3.160.3%, P,0.05). The
vast majority of dead TSCs detected after 7 days of hypoxia were
positive for Annexin V and PI, indicating that cell death was
mainly due to late apoptosis (Figure 4A–C). Inhibition of PP2A
gave rise to a massive increase of Annexin V+/PI+ cells during
hypoxic conditions (Figure 4A–C). We then transduced TSCs with
shRNA targeted against random RNA (control), PP2A-C, and
PME-1. In annexin/PI cytometry experiments, depletion of PP2A-
C had similar effects as OA. Thus, PP2A-C depleted TSCs
exhibited significantly higher rates of cell death following culture
in hypoxic conditions compared to culture in standard conditions
(Figure 4D). Importantly, enhancement of PP2A signaling by
depletion of PME-1 as previously described [19] decreased levels
of cell death in hypoxic conditions to levels comparable to
normoxic conditions. In line with previous reports [37,38], we
detected increased levels of posphorylated PLK and AKT in
hypoxic cells treated with OA (Figure 4E). We then investigated
the role of P53 in cell death of hypoxic TSCs during PP2A
inhibition (Figure S4). Severe hypoxia led to dephosphorylation of
P53 at the serine15 residue and reduction of P53 expression in
TSCs. Treatment with OA partially restored P53 expression in
hypoxic TSCs. In order to investigate whether P53 mediates TSC
death during hypoxia with concurrent PP2A inhibition, we
Figure 2. Hypoxia increases cyclin G2 expression and PP2A activity in TSCs. (A) At 2, 4, 6, 8, 12, and 24 hours following addition of CoCl2 to
culture media, HIF-1a protein is detected in TSCs while cells grown in standard conditions lack expression. Increased cyclin G2 levels are detected in
TSCs six hours following exposure to CoCl2. Expression levels of the PP2A C subunit remain stable throughout the experiment. Bar graph depicts
marked increase of PP2A activity following exposure of TSCs to CoCl2. Thus, PP2A activity levels are nine times higher in TSCs propagated in CoCl2 for
six hours compared to TSCs grown in standard conditions. Bars represent the mean value of 3 independent experiments 6 SEM. (B) To determine
whether PP2A directly interacts with cyclin G2, PP2A was immunoprecipitated in cell lysates from control TSCs and TSCs exposed to six hours of
CoCl2. In both conditions, the PP2A C subunit forms a complex with cyclin G2.
doi:10.1371/journal.pone.0030059.g002
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P53 depletion did not alter the amount of cell death during
hypoxic culture conditions with concurrent PP2A inhibition.
Discussion
In the current study, we propose that increased PP2A activity
predicts poor outcome in patients with GBM. In vitro experiments
suggest that hypoxia induces PP2A activity in GBM-derived TSCs.
Hypoxia-induced PP2A decreases metabolic activity by halting cell
proliferation and enhances survival of TSCs in a severely hypoxic
environment.
Severely hypoxic GBM with high PP2A activity carried a poor
prognosis in our patient cohort. Several studies have linked
severity of hypoxia in malignant astrocytoma with a more
aggressive clinical course [6,39]. Evans and colleagues measured
tissue hypoxia using the 2-nitroimidazol agent EF5 and demon-
strated modest cellular hypoxia in low-grade astrocytomas (WHO
grade 2) and severe levels of hypoxia in GBMs (WHO grade 4) [6].
Thus, severity of hypoxia was correlated with histological tumor
grade in malignant astrocytomas [6,39]. However, when account-
ing for tumor grade, HIF-1/ was no longer an independent
predictor of survival [39]. This is similar to findings in our series.
While HIF-1/ was a predictor of survival performing a univariate
analysis, statistical significance was lost on multivariable analysis
(data not shown). Given the strong association between HIF-1a
and PP2A, one may question why PP2A activity is an independent
predictor of survival. It may be speculated that PP2A-mediated
dormancy of TSCs protects tumor cells from a variety of other
toxic factors such as deprivation of nutrition or exposure to
chemotherapy or irradiation.
Brain tumors have high glucose consumption since tumor cells
commonly use inefficient glycolysis for ATP production
[40,41,42]. Thus, decreased glucose concentration is a common
finding in centers of solid brain tumors [43,44]. Glucose
deprivation combined with hypoxia results in cell death of
malignant glioma cell lines with phenotypic features of late
apoptosis/necrosis [45]. We similarly showed that the major
phenotype of cell death in hypoxic TSCs during PP2A inhibition
was late apoptosis/necrosis. Conversely, acute apoptosis was
almost absent. Interestingly, a recent study demonstrated a
dramatic increase of hypoxia-induced cell death in HIF-1/-
depleted ovarian cancer cells [46]. Similar to PP2A inhibition,
HIF-1/ depletion prevented cancer cells from arresting in the
G1/S phase during hypoxic conditions. HIF-1/- depleted cancer
cells continued to proliferate, depleted intracellular ATP levels,
and eventually acceleration of late apoptosis/necrosis. Cell death
may have been caused by the lack of mitochondrial shut-down
during severe hypoxia leading to production of reactive oxygen
species and concomitant cell death.
There is also a body of literature suggesting that PP2A plays a
critical role in activation of DNA damage checkpoints, which leads
to arrest of cell cycle progression and allows for DNA repair
[47,48,49,50]. Specifically, PP2A has been shown to mediate the
DNA damage checkpoint responses by activating ATR and Chk1
kinases following c-irradiation [51]. Moreover, DNA damage by
chemotherapy or radiation has been proposed to activate the
DNA damage checkpoint via PP2A-mediated dephosporylation of
PLK [52]. PP2A inhibition leads to phosophorylation and
activation of PLK and allows for enhanced anticancer activity of
chemotherapy directed against a GBM cell line [37] as well as a
pheochromocytoma cell line [38]. Thus, PP2A might promote
tumor cell survival via halting cell cycle progression in response to
a variety of cell-toxic environmental factors.
In our experiments, we found that severe hypoxia (1% O2)o r
CoCl2 induces PP2A activity in TSCs in vitro. Increased PP2A
activity in response to hypoxia has been previously reported in a
model of transient cerebral ischemia with reperfusion in vivo [10].
Similarly, hypoxic culture conditions give rise to increased PP2A
activity in cortical primary astrocytes in vitro [11]. The detailed
composition of the hypoxia-induced PP2A complex and possible
mechanisms of PP2A activation remain area of intensive research.
We speculate that hypoxia-induced PP2A forms a complex with
cyclin G2 to affect cell cycle progression. In line with previous
studies, we found that cyclin G2 was upregulated during hypoxic
conditions [23,24,53] and increased cyclin G2 protein levels
mirrored the increase in PP2A activity. Cyclin G2 is an
unconventional cyclin that leads to G1/S cell cycle arrest by
inhibition of CDK2 activity independent of P53 [21]. Importantly,
cyclin G2 forms a complex with PP2A, and its phosphatase activity
is suppressed by low doses of okadaic Acid (OA, ,2 nM) [21].
Moreover, in line with observations by Bennin and colleagues
[21], low doses of OA (1 nM) were sufficient to partially reverse
G1/S cell cycle arrest in hypoxic cells. Thus, we suggest that PP2A
contributes to the G1/S phase arrest in combination with cyclin
G2 during hypoxic conditions. In our in vitro experiments, we
observed adaptive changes of RTK/RAS/PI3K signaling in TSCs
in response to hypoxia consistent with previous literature
[54,55,56]. Regulation of RTK/RAS/PI3K signaling aims to
regulate metabolic functions and proliferation in order to optimize
survival under hypoxic conditions. PP2A has been shown to
interact with RTK/RAS/PI3K signaling at multiple levels and is
mainly opposing its effects (for review, please see [57]). One may
speculate that the necrotic-like cell death observed in our model
following PP2A inhibition may have resulted from increased AKT
activity and subsequent enhancement of metabolic activity and cell
proliferation in a non-growth-permissive hypoxic environment.
PP2A inhibition has been proposed to increase tumor cell death
during chemotherapy via a similar mechanism [37,38]. Moreover,
inhibition of RTK/RAS/PI3K signaling has been suggested to
increase cell survival during hypoxic conditions [58]. Thus, Satoh
and colleagues found that a MAPK/ERK kinase inhibitor
(U0126) promoted survival of primary cortical cultures during
severe hypoxia (O2,0.2%).
Figure 3. PP2A reduces ATP consumption and inhibits growth of TSCs during hypoxic conditions. (A) Effect of PP2A inhibition on ATP
consumption of TSCs during normoxia and hypoxia. Intracellular ATP was measured in TSCs 1 hour following substrate depletion (D5030 media) with
our without PP2A inhibition. PP2A inhibition leads to significantly higher ATP consumption during hypoxic conditions. The ATP content was
measured and normalized to the lysate protein content. Bars represent the mean values of 8 independent experiments 6 SEM. (B) 24 hours following
plating, TSCs are exposed to CoCl2 and/or OA for additional 24 hours. Hypoxia leads to G1/S phase growth inhibition in TSCs. Representative
examples of cell cycle analysis experiments. (C) Summary of six independent experiments reveals that hypoxia-mediated G1/S phase arrest is partially
reversed by OA in a dose-dependent fashion. Accordingly, PP2A inhibition allows for significantly more hypoxic TSCs to progress into the S-phase. (D)
In line with pharmacological inhibition of PP2A, depletion of PP2A by shRNA alleviates G1/S cell cycle arrest in TSCs propagated in CoCl2. Given the
longer duration of PP2A inhibition in PP2A-depleted cells (48 h) compared to OA-treated cells (24 h [C]), more PP2A-depleted cells progress to G2
phase. Increasing PP2A activity by depletion of the endogenous PP2A inhibitor PME-1 has the opposite effect. Western blots reveal depletion of
PP2A-C and PME-1 in TSCs by shRNA.
doi:10.1371/journal.pone.0030059.g003
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response to hypoxia, several areas require further investigation
prior to the design of PP2A-based experimental therapies. First,
the composition of hypoxia-induced PP2A heterotrimers and the
mechanism of their activation [12,59] are poorly understood.
Moreover, since PP2A activity is involved in numerous cellular
processes, systemic PP2A inhibition would also affect PP2A
signaling in normoxic tissues, possibly causing adverse effects.
This is of particular importance since the therapeutic range of
pharmacological PP2A inhibition targeting hypoxic cells is
narrow. Moreover, OA is not a specific inhibitor for PP2A [60].
While OA doses used in the current study are similar to the IC50
dose for PP2A inhibition (0.1 nM) [15], OA at higher concentra-
tions (IC50=10 nM) also blocks PP1. However, results from
Figure 4. PP2A inhibition enhances cell death of hypoxic TSCs. (A) Examples of Annexin/PI stainings of TSCs grown for seven days in either
normal culturing conditions or in media supplemented with 200 mM of CoCl2. Addition of 1 nM of OA has no significant effect on cells propagated in
normal culturing conditions, but significantly increases the number of Annexin V+/PI+ cells in hypoxic conditions. (B) Photographs of TSCs in vitro
following one week of culture during normoxia or hypoxia with or without inhibition of PP2A. Viable cells are stained by formazan dye. Few viable
cells (black, arrows) are seen in hypoxic cells exposed to OA. (C) While neither 0.5 nM nor 1 nM of OA exerts a significant effect on the death of TSCs
in routine culturing conditions, OA significantly increases the amount of Annexin V+/PI+ TSCs during hypoxic conditions. Bars represent the mean
value of 6 independent experiments 6 SEM. (D) Depletion of the PP2A-C causes an almost two-fold increase of cell death during hypoxic conditions.
Importantly, enhancement of PP2A activity by PME-1 depletion reduces death of hypoxic TSCs to levels comparable to normoxia. (E) Inhibition of
PP2A in TSCs exposed to hypoxic conditions for 3 days leads to increased phosphorylation of PLK and AKT.
doi:10.1371/journal.pone.0030059.g004
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inhibition in combination with chemotherapy are encouraging.
PP2A-inhibition increased the anticancer effect of temazolomide
in xenograft mouse model for GBM and neuroblastoma [37].
Systemic PP2A-inhibition was tolerated in rodents, and no adverse
effects were reported during a short follow-up period [37,38].
In conclusion, increased PP2A activity is detected in hypoxic
GBM specimens of patients carrying the worst prognosis. PP2A
mediates reduction of energy consumption of hypoxic TSCs,
which enhances tumor cell survival. Future studies need to address
whether increased PP2A activity also contributes to the increased
therapy resistance of hypoxic tumor cells [9] and to further
examine possible synergistic effects of chemotherapy with PP2A
inhibition [37,38]. Hypoxia-induced PP2A activity promotes
survival of TSCs and may be a possible target for experimental
cytotoxic therapies.
Supporting Information
Figure S1 Single cell clonal analysis for stemness and differen-
tiation. Dissociated GBM tissue was seeded on laminin coated
10 cm dishes (3610
6 cells per dish) (A). Single cells were isolated
and plated into 24 well plates (B) and subpopulations were isolated
after 2 weeks (C). TSCs were allowed to grow on cover slips to
perform immunocytochemistry to investigate the expression of
stem cell markers (D). Cell differentiation was induced by culturing
TSCs in media without growth factors (bFGF and EGF) and
supplemented with serum. Following 30 days of culture in
differentiating conditions, TSCs underwent immunocytochemistry
for common markers of differentiation (E).
(TIF)
Figure S2 Hypoxia induces PP2A activity independent of HIF-
2a expression. (A) TSCs exhibit elevated HIF-2a protein
expression 72 hours following exposure to 1% hypoxia, while
increased cyclin G2 and hypoxia-induced PP2A activity (bar
graph) are seen from 12 hours onwards. Bars represent the mean
value of 3 independent experiments 6 SEM. (B) Two out of three
TSCs express increased HIF-2a protein levels 72 hours following
exposure to hypoxia. No detectable HIF-2a is seen in non-stemcell
glioblastoma cells (U87) or in TSCs that are differentiated by FBS
(10%) containing media without growth factors for 30 days. Cell
lysates were also probed with antibodies directed against the A, B
and C subunits of PP2A. Hypoxia induces PP2A activity in both
TSCs and a non-stemcell tumor cell line (U87). Low PP2A activity
is detected in differentiated TSCs. Bars represent the mean value
of 3 independent experiments 6 SEM.
(TIF)
Figure S3 PP2A mediates reduction of metabolic activity and
ATP production during hypoxia. (A) MTT assay reveals partial
reversal of hypoxia-mediated growth arrest by PP2A inhibition.
Cells are either grown in standard media or in 200 mM CoCl2 for
24 hours supplemented with either 0.5 or 1 nM of OA. (B and C)
Exposure of hypoxic TSCs to either one or two weeks of 0.1, 0.5
or 1 nM of OA leads to a significant decrease of cell proliferation
and viability as determined by MTT. Each bar represents the
mean value of 4 independent experiments 6 SEM. (D)
Measurement of intracellular ATP levels in TSCs in response to
hypoxia (1% O2). PP2A inhibition significantly delays initial ATP
decay seen in hypoxic TSCs within the first 6 to 24 hours.
Eventually, PP2A inhibition causes exhaustion of intracellular
ATP in hypoxic TSCs. Following 1 and 2 weeks of hypoxia,
intracellular ATP levels are significantly decreased in cells treated
with OA. Each data point represents the mean value of 6
independent experiments 6 SEM. (E) Glucose supplementation
partially reverses OA-mediated exhaustion of intracellular ATP
levels. TSCs were grown for 1 week in hypoxic conditions (1% O2)
in high or low glucose media with or without OA followed by
measurement of intracellular ATP levels. Each bar represents the
mean value of 6 independent experiments 6 SEM.
(TIF)
Figure S4 PP2A inhibition enhances death of hypoxic TSCs in a
P53-independent fashion (A) Exposure of TSCs to 200 mMo f
CoCl2 induces HIF-1a at all time intervals tested. P53 expression
decreases in a time-dependent pattern following incubation with
CoCl2. Hypoxia is associated with dephosphorylation of P53 at the
S15. Bar graph shows the mean phosphorylation coefficient of
three independent experiments. (B) TSCs are grown in normal or
in CoCl2-supplemented culture conditions for six hours. Addition
of 0.1 or 1 nM of OA has little effect on P53 expression in
normoxic conditions; however, in hypoxic conditions, inhibition of
PP2A leads to a dose-dependent recovery of P53 expression. Bar
graph depicts mean PP2A activity of 3 independent experiments
6 SEM. (C) Western blot demonstrates that shRNA depletes p53
in TSCs. P53 depletion does not alter cell death observed in TSCs
cultured in 200 mM CoCl2 for one week with concurrent PP2A
inhibition.
(TIF)
Acknowledgments
We would like to thank Dr. Sergei Rudchenko and Stanka Semova for
excellent assistance with performing flow cytometry.
Author Contributions
Conceived and designed the experiments: CPH JAB ECH. Performed the
experiments: CPH JB BJS DBG LM RG. Analyzed the data: CPH BJS RG
CB. Contributed reagents/materials/analysis tools: CPH ECH JAB. Wrote
the paper: CPH ECH JAB.
References
1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
N Engl J Med 352: 987–996.
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The
2007 WHO classification of tumours of the central nervous system. Acta
Neuropathol 114: 97–109.
3. (2008) Comprehensive genomic characterization defines human glioblastoma
genes and core pathways. Nature 455: 1061–1068.
4. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, et al. (1985)
Amplification, enhanced expression and possible rearrangement of EGF
receptor gene in primary human brain tumours of glial origin. Nature 313:
144–147.
5. Westermark B, Heldin CH, Nister M (1995) Platelet-derived growth factor in
human glioma. Glia 15: 257–263.
6. Evans SM, Judy KD, Dunphy I, Jenkins WT, Hwang WT, et al. (2004) Hypoxia
is important in the biology and aggression of human glial brain tumors. Clin
Cancer Res 10: 8177–8184.
7. Hamada K, Kuratsu J, Saitoh Y, Takeshima H, Nishi T, et al. (1996) Expression
of tissue factor in glioma. Noshuyo Byori 13: 115–118.
8. Brat DJ, Castellano-Sanchez AA, Hunter SB, Pecot M, Cohen C, et al. (2004)
Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix
proteases, and are formed by an actively migrating cell population. Cancer
Res 64: 920–927.
9. Amberger-Murphy V (2009) Hypoxia helps glioma to fight therapy. Curr
Cancer Drug Targets 9: 381–390.
10. Zhang TT, Platholi J, Heerdt PM, Hemmings HC, Jr., Tung HY (2008) Protein
phosphatase-2A is activated in pig brain following cardiac arrest and
resuscitation. Metab Brain Dis 23: 95–104.
PP2A Mediates Dormancy of Hypoxic TSCs
PLoS ONE | www.plosone.org 10 January 2012 | Volume 7 | Issue 1 | e3005911. Yung HW, Tolkovsky AM (2003) Erasure of kinase phosphorylation in
astrocytes during oxygen-glucose deprivation is controlled by ATP levels and
activation of phosphatases. J Neurochem 86: 1281–1288.
12. Heikkinen PT, Nummela M, Leivonen SK, Westermarck J, Hill CS, et al. (2009)
Hypoxia-activated Smad3-specific dephosphorylation by PP2A. J Biol Chem
285: 3740–3749.
13. Cho US, Xu W (2007) Crystal structure of a protein phosphatase 2A
heterotrimeric holoenzyme. Nature 445: 53–57.
14. Janssens V, Goris J (2001) Protein phosphatase 2A: a highly regulated family of
serine/threonine phosphatases implicated in cell growth and signalling.
Biochem J 353: 417–439.
15. MacKintosh C, Cohen P (1989) Identification of high levels of type 1 and type
2A protein phosphatases in higher plants. Biochem J 262: 335–339.
16. Suganuma M, Fujiki H, Suguri H, Yoshizawa S, Hirota M, et al. (1988) Okadaic
acid: an additional non-phorbol-12-tetradecanoate-13-acetate-type tumor pro-
moter. Proc Natl Acad Sci U S A 85: 1768–1771.
17. Fujiki H, Suganuma M (1993) Tumor promotion by inhibitors of protein
phosphatases 1 and 2A: the okadaic acid class of compounds. Adv Cancer Res
61: 143–194.
18. Casillas AM, Amaral K, Chegini-Farahani S, Nel AE (1993) Okadaic acid
activates p42 mitogen-activated protein kinase (MAP kinase; ERK-2) in B-
lymphocytes but inhibits rather than augments cellular proliferation: contrast
with phorbol 12-myristate 13-acetate. Biochem J 290(Pt 2): 545–550.
19. Puustinen P, Junttila MR, Vanhatupa S, Sablina AA, Hector ME, et al. (2009)
PME-1 protects extracellular signal-regulated kinase pathway activity from
protein phosphatase 2A-mediated inactivation in human malignant glioma.
Cancer Res 69: 2870–2877.
20. Fishbein JD, Dobrowsky RT, Bielawska A, Garrett S, Hannun YA (1993)
Ceramide-mediated growth inhibition and CAPP are conserved in Saccharo-
myces cerevisiae. J Biol Chem 268: 9255–9261.
21. Bennin DA, Don AS, Brake T, McKenzie JL, Rosenbaum H, et al. (2002)
Cyclin G2 associates with protein phosphatase 2A catalytic and regulatory B9
subunits in active complexes and induces nuclear aberrations and a G1/S phase
cell cycle arrest. J Biol Chem 277: 27449–27467.
22. Horne MC, Donaldson KL, Goolsby GL, Tran D, Mulheisen M, et al. (1997)
Cyclin G2 is up-regulated during growth inhibition and B cell antigen receptor-
mediated cell cycle arrest. J Biol Chem 272: 12650–12661.
23. Ragel BT, Couldwell WT, Gillespie DL, Jensen RL (2007) Identification of
hypoxia-induced genes in a malignant glioma cell line (U-251) by cDNA
microarray analysis. Neurosurg Rev 30: 181–187; discussion 187.
24. Bando H, Toi M, Kitada K, Koike M (2003) Genes commonly upregulated by
hypoxia in human breast cancer cells MCF-7 and MDA-MB-231. Biomed
Pharmacother 57: 333–340.
25. Leonard MO, Cottell DC, Godson C, Brady HR, Taylor CT (2003) The role of
HIF-1 alpha in transcriptional regulation of the proximal tubular epithelial cell
response to hypoxia. J Biol Chem 278: 40296–40304.
26. Hofstetter CP, Mannaa RH, Mubita L, Anand VK, Kennedy JW, et al. (2010)
Endoscopic endonasal transsphenoidal surgery for growth hormone-secreting
pituitary adenomas. Neurosurg Focus 29: E6.
27. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, et al. (2008) Analysis
of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:
597–602.
28. Bleeker FE, Atai NA, Lamba S, Jonker A, Rijkeboer D, et al. (2010) The
prognostic IDH1(R132) mutation is associated with reduced NADP+-dependent
IDH activity in glioblastoma. Acta Neuropathol 119: 487–494.
29. Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, et al. (2009) Glioma
stem cell lines expanded in adherent culture have tumor-specific phenotypes and
are suitable for chemical and genetic screens. Cell Stem Cell 4: 568–580.
30. Gursel D, Shin BJ, Burkhardt J, Kesavabhotla K, Schlaff CD, et al. (2011)
Glioblastoma Stem-Like Cells - Biology and Therapeutic Implications. Cancers
3: 2655–2666.
31. Gursel DB, Beyene RT, Hofstetter C, Greenfield JP, Souweidane MM, et al.
(2011) Optimization of glioblastoma multiforme stem cell isolation, transfection,
and transduction. J Neurooncol.
32. Christensen E (1987) Multivariate survival analysis using Cox’s regression model.
Hepatology 7: 1346–1358.
33. Colella S, Ohgaki H, Ruediger R, Yang F, Nakamura M, et al. (2001) Reduced
expression of the Aalpha subunit of protein phosphatase 2A in human gliomas in
the absence of mutations in the Aalpha and Abeta subunit genes. Int J Cancer
93: 798–804.
34. Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, et al. (2008)
Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 62: 564–576; discussion 564–576.
35. Ivan M, Kondo K, Yang H, Kim W, Valiando J, et al. (2001) HIFalpha targeted
for VHL-mediated destruction by proline hydroxylation: implications for O2
sensing. Science 292: 464–468.
36. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, et al. (2001) Targeting
of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated
prolyl hydroxylation. Science 292: 468–472.
37. Lu J, Kovach JS, Johnson F, Chiang J, Hodes R, et al. (2009) Inhibition of
serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking
DNA damage induced defense mechanisms. Proc Natl Acad Sci U S A 106:
11697–11702.
38. Martiniova L, Lu J, Chiang J, Bernardo M, Lonser R, et al. (2011)
Pharmacologic Modulation of Serine/Threonine Phosphorylation Highly
Sensitizes PHEO in a MPC Cell and Mouse Model to Conventional
Chemotherapy. PLoS One 6: e14678.
39. Korkolopoulou P, Patsouris E, Konstantinidou AE, Pavlopoulos PM,
Kavantzas N, et al. (2004) Hypoxia-inducible factor 1alpha/vascular endothelial
growth factor axis in astrocytomas. Associations with microvessel morphometry,
proliferation and prognosis. Neuropathol Appl Neurobiol 30: 267–278.
40. Heller IH, Elliott KA (1955) The metabolism of normal brain and human
gliomas in relation to cell type and density. Can J Biochem Physiol 33: 395–403.
41. Mahaley MS, Jr. (1966) The in vitro respiration of normal brain and brain
tumors. Cancer Res 26: 195–197.
42. Warburg O (1926) U ¨ber den Stoffwechsel von Tumoren. Berlin: Springer.
43. Hossmann KA, Mies G, Paschen W, Szabo L, Dolan E, et al. (1986) Regional
metabolism of experimental brain tumors. Acta Neuropathol 69: 139–147.
44. Mies G, Paschen W, Ebhardt G, Hossmann KA (1990) Relationship between of
blood flow, glucose metabolism, protein synthesis, glucose and ATP content in
experimentally-induced glioma (RG1 2.2) of rat brain. J Neurooncol 9: 17–28.
45. Steinbach JP, Wolburg H, Klumpp A, Probst H, Weller M (2003) Hypoxia-
induced cell death in human malignant glioma cells: energy deprivation
promotes decoupling of mitochondrial cytochrome c release from caspase
processing and necrotic cell death. Cell Death Differ 10: 823–832.
46. Favaro E, Nardo G, Persano L, Masiero M, Moserle L, et al. (2008) Hypoxia
inducible factor-1alpha inactivation unveils a link between tumor cell
metabolism and hypoxia-induced cell death. Am J Pathol 173: 1186–1201.
47. Chowdhury D, Keogh MC, Ishii H, Peterson CL, Buratowski S, et al. (2005)
gamma-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA
double-strand break repair. Mol Cell 20: 801–809.
48. Goodarzi AA, Jonnalagadda JC, Douglas P, Young D, Ye R, et al. (2004)
Autophosphorylation of ataxia-telangiectasia mutated is regulated by protein
phosphatase 2A. EMBO J 23: 4451–4461.
49. Li G, Elder RT, Qin K, Park HU, Liang D, et al. (2007) Phosphatase type 2A-
dependent and -independent pathways for ATR phosphorylation of Chk1. J Biol
Chem 282: 7287–7298.
50. Li HH, Cai X, Shouse GP, Piluso LG, Liu X (2007) A specific PP2A regulatory
subunit, B56gamma, mediates DNA damage-induced dephosphorylation of p53
at Thr55. EMBO J 26: 402–411.
51. Yan Y, Cao PT, Greer PM, Nagengast ES, Kolb RH, et al. (2010) Protein
phosphatase 2A has an essential role in the activation of gamma-irradiation-
induced G2/M checkpoint response. Oncogene 29: 4317–4329.
52. Jang YJ, Ji JH, Choi YC, Ryu CJ, Ko SY (2007) Regulation of Polo-like kinase 1
by DNA damage in mitosis. Inhibition of mitotic PLK-1 by protein phosphatase
2A. J Biol Chem 282: 2473–2482.
53. Wykoff CC, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ (2000)
Identification of novel hypoxia dependent and independent target genes of the
von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression
profiling. Oncogene 19: 6297–6305.
54. Mazure NM, Chen EY, Laderoute KR, Giaccia AJ (1997) Induction of vascular
endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-
kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia
inducible factor-1 transcriptional element. Blood 90: 3322–3331.
55. Chen EY, Mazure NM, Cooper JA, Giaccia AJ (2001) Hypoxia activates a
platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt path-
way that results in glycogen synthase kinase-3 inactivation. Cancer Res 61:
2429–2433.
56. Kawano T, Fukunaga K, Takeuchi Y, Morioka M, Yano S, et al. (2001)
Neuroprotective effect of sodium orthovanadate on delayed neuronal death after
transient forebrain ischemia in gerbil hippocampus. J Cereb Blood Flow Metab
21: 1268–1280.
57. Junttila MR, Li SP, Westermarck J (2008) Phosphatase-mediated crosstalk
between MAPK signaling pathways in the regulation of cell survival. FASEB J
22: 954–965.
58. Satoh T, Nakatsuka D, Watanabe Y, Nagata I, Kikuchi H, et al. (2000)
Neuroprotection by MAPK/ERK kinase inhibition with U0126 against
oxidative stress in a mouse neuronal cell line and rat primary cultured cortical
neurons. Neurosci Lett 288: 163–166.
59. Heikkinen PT, Nummela M, Jokilehto T, Grenman R, Kahari VM, et al. (2010)
Hypoxic conversion of SMAD7 function from an inhibitor into a promoter of
cell invasion. Cancer Res 70: 5984–5993.
60. Cohen P, Holmes CF, Tsukitani Y (1990) Okadaic acid: a new probe for the
study of cellular regulation. Trends Biochem Sci 15: 98–102.
PP2A Mediates Dormancy of Hypoxic TSCs
PLoS ONE | www.plosone.org 11 January 2012 | Volume 7 | Issue 1 | e30059